Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pasireotide - RECORDATI

Next Previous
Drug Profile

Pasireotide - RECORDATI

Alternative Names: Pashireochidopamo salt; pasireotide LAR; Pasireotide pamoate; SIGNIFOR; SIGNIFOR LAR; SOM 230; SOM 230 LAR; SOM230C

Latest Information Update: 16 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Novartis; Recordati; UNC Lineberger Comprehensive Cancer Center; University of Arkansas for Medical Sciences; University of Miami
  • Class Analgesics; Antihypoglycaemics; Antineoplastics; Antisecretories; Cyclic peptides; Macrocyclic compounds; Oligopeptides; Peptidomimetics
  • Mechanism of Action Corticotropin-releasing hormone inhibitors; Growth hormone-releasing hormone inhibitors; Insulin-like growth factor I inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly; Pituitary ACTH hypersecretion; Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acromegaly; Gigantism; Pituitary ACTH hypersecretion
  • Phase II Cluster headache; Hypoglycaemia; Pituitary cancer
  • Discontinued Carcinoid tumour; Gastrointestinal cancer; Gastrointestinal disorders; Liver cancer; Malignant melanoma; Meningioma; Merkel cell carcinoma; Neuroendocrine tumours; Pancreatic cancer; Pancreatic disorders; Prostate cancer; Radiation injuries; Uveal melanoma

Most Recent Events

  • 03 Feb 2026 Recordati completes a phase I trial (In volunteers) in the Germany (NCT07312643)
  • 01 Dec 2025 Recordati initiates a phase I trial (In volunteers) in the Germany (NCT07312643) (EudraCT2024-519165-22-00) (CTIS2024-519165-22-00)
  • 01 Aug 2025 Recordati completes enrolment in its phase II trial for Hypoglycaemia in United Kingdom, Spain, Italy, France, Belgium, USA (SC) (NCT05928390)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top